Leerink Partners analyst Thomas Smith reiterated a Buy rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) Inc on Thursday, setting a price target of $145, which is approximately 11.18% above the present share price of $130.42.
Smith expects Madrigal Pharmaceuticals Inc to post earnings per share (EPS) of -$3.82 for the second quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Madrigal Pharmaceuticals, with an average price target of $172.09.
The analysts price targets range from a high of $225 to a low of $129.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$59.56 million. The company's market cap is $2.15 billion.
According to TipRanks.com, Leerink Partners analyst Thomas Smith is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.4% and a 31.71% success rate.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.